Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of EPI-589 re-administration for amyotrophic lateral sclerosis
jRCTs051230064Completed
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of EPI-589 in amyotrophic lateral sclerosis (ALS). Primary endpoint: Adverse events. Started Aug 2023; status: completed.
02
Drugs
EPI-589
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCTs051230064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230064.